Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Fineline Cube Jan 23, 2026
Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Fineline Cube Jan 23, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

Skyline Therapeutics’ Gene Therapy Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment

Fineline Cube Sep 4, 2024

Skyline Therapeutics, a biopharmaceutical company based in China, has received Orphan Drug Designation (ODD) from...

Company Deals

CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline

Fineline Cube Sep 4, 2024

CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a...

Company Drug

Innovent Biologics’ IBI363 Earns FDA Fast-Track Designation for Advanced Melanoma Treatment

Fineline Cube Sep 4, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has received fast-track...

Company Medical Device

Jafron Biomedical’s Blood Purification Devices Gain EU Market Approval Under MDR

Fineline Cube Sep 4, 2024

Jafron Biomedical Co., Ltd, a prominent player in the blood purification sector based in China,...

Policy / Regulatory

China’s 13 Ministries Unite to Chart a Healthier Future for Rural Communities

Fineline Cube Sep 4, 2024

China’s National Health Commission (NHC), in collaboration with the National Development and Reform Commission, Ministry...

Company Drug

Humanwell Healthcare’s Innovative Drug for Solid Tumors Gets Green Light from NMPA

Fineline Cube Sep 4, 2024

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading pharmaceutical entity in China, has received...

Company Drug

Jiangsu Hengrui and Chongqing Genrix Launch Anti-IL-17 Therapies for Psoriasis in China

Fineline Cube Sep 4, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) and Chongqing Genrix Biopharmaceutical Co., Ltd, two leading...

Policy / Regulatory

China Unveils Blueprint for Service Trade Expansion through Strategic Opening Up

Fineline Cube Sep 4, 2024

China’s State Council has issued a strategic directive titled “Opinions on Promoting the High-quality Development...

Policy / Regulatory

China’s NHC Charts Ambitious Healthcare Reform Path with Emphasis on TCM and Technology

Fineline Cube Sep 4, 2024

Lei Haichao, Director of China’s National Health Commission (NHC), has outlined a comprehensive reform agenda...

Company Deals

EpimAb’s EMB-06 Secures $635 Million Licensing Agreement with Vignette for Multiple Myeloma Therapy

Fineline Cube Sep 4, 2024

EpimAb Biotherapeutics, a Shanghai-based biotech firm, has inked a licensing deal with Vignette for the...

Company Drug

Sanofi’s Tolebrutinib Shows Mixed Results in Phase III Multiple Sclerosis Trials

Fineline Cube Sep 3, 2024

PARIS—French pharmaceutical giant Sanofi (NASDAQ: SNY) has reported mixed outcomes from three Phase III trials...

Company Drug

Bayer’s Finerenone Shows Promise in Heart Failure Treatment, Outperforms Placebo in Phase III Trial

Fineline Cube Sep 3, 2024

FRANKFURT—Bayer AG (FRA: BAYN) has announced positive results from the Phase III FINEARTS-HF study for...

Company Drug

Henlius Biotech’s HLX17 Biosimilar to MSD’s Keytruda Wins NMPA Clinical Trial Approval

Fineline Cube Sep 3, 2024

SHANGHAI—Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clinical trial approval...

Company Drug

Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablet Earns FDA Breakthrough Therapy Designation for Stroke Treatment

Fineline Cube Sep 3, 2024

HONG KONG—Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received Breakthrough...

Company Deals

Jiangsu Simcere Acquires Exclusive Rights to TargetRx’s TGRX-326 in Licensing Deal

Fineline Cube Sep 3, 2024

SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing...

Company Drug

GeneQuantum Healthcare’s GQ1005 ADC Receives CDE Clearance for Phase III Breast Cancer Trial

Fineline Cube Sep 3, 2024

SUZHOU—GeneQuantum Healthcare (Suzhou) Co., Ltd has received clearance from the Center for Drug Evaluation (CDE)...

Company Medical Device

Beijing Balance Medical Secures NMPA Nod for Renatus Transcatheter Aortic Valve System

Fineline Cube Sep 3, 2024

BEIJING—Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has received market approval from the National...

Company Drug

Sinocelltech’s Anti-Angiogenic Biologic SCT520FF Gets NMPA Green Light for Neovascular AMD Clinical Study

Fineline Cube Sep 3, 2024

SHANGHAI—Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that it has received...

Company Deals

Zhejiang Dian Diagnostics Partners with Shanghai Mycology Lab to Advance Fungal Infection Diagnostics

Fineline Cube Sep 3, 2024

SHANGHAI—Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading player in the diagnostics industry, has...

Company Deals

Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024

Fineline Cube Sep 3, 2024

SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...

Posts pagination

1 … 250 251 252 … 613

Recent updates

  • Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
  • Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy
  • Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base
  • BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector
  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer

Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Company Deals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.